Trial Profile
Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Nov 2022
Price :
$35
*
At a glance
- Drugs TAC 302 (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- Sponsors Taiho Pharmaceutical
- 01 Nov 2022 Primary endpoint has been met, (Male; bladder contractility index (BCI), as per as per Results published in the World Journal of Urology
- 01 Nov 2022 Primary endpoint has been met, (Female; projected isovolumetric pressure (PIP) 1), as per Results published in the World Journal of Urology
- 01 Nov 2022 Results published in the World Journal of Urology